ABL1 and chronic myelogenous leukemia, BCR-ABL1 positive: To the delight of CML patients, asciminib was approved by the US FDA in 2021 to treat patients with CML who suffer resistance to or unacceptable adverse effects from TKIs or with the BCR-ABL-T315I mutation.